MAP2K7 and neoplasm: 2008; Kudo 2012). Its mechanism of action is to inhibit the proliferation of tumor cells by inhibiting the receptor tyrosine kinase KIT and FLT-3 and the Raf/MEK/ERK serine/threonine kinase pathway (Strumberg et al. 2007; Miller et al. 2009; Abdel-Rahman & Elsayed 2013; Shimada et al. 2014). It inhibits neoplastic angiopoiesis by inhibiting the upstream VEGFR and PDGFR and the downstream Raf/MEK/ERK pathway. However, its low oral bioavailability (Liu et al. 2016) and side reactions (Strumberg 2012) greatly limit its clinical application.